{"id":"kl1333","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Fatigue"},{"rate":"5-10%","effect":"Nausea"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":{"chemblId":"CHEMBL4594430","moleculeType":"Small molecule","molecularWeight":"240.26"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the mPTP, KL1333 triggers a rapid and irreversible cell death in cancer cells, making it a potential therapeutic agent for various types of cancer. This mechanism of action is distinct from traditional chemotherapy and radiation therapy, which often cause damage to both cancer and healthy cells.","oneSentence":"KL1333 is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to induce cell death in cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:58:10.745Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Treatment of various types of cancer, including glioblastoma and melanoma"}]},"trialDetails":[{"nctId":"NCT05650229","phase":"PHASE2","title":"Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease","status":"RECRUITING","sponsor":"Abliva AB","startDate":"2022-12-13","conditions":"Primary Mitochondrial Disease","enrollment":180},{"nctId":"NCT03888716","phase":"PHASE1","title":"A Phase Ia/Ib, SAD and MAD Study of of KL1333 in Healthy Subjects and Patients With Primary Mitochondrial Disease","status":"COMPLETED","sponsor":"Abliva AB","startDate":"2019-03-18","conditions":"Mitochondrial Diseases, Mitochondrial Respiratory Chain Deficiencies, MELAS Syndrome","enrollment":72},{"nctId":"NCT04643249","phase":"PHASE1","title":"Drug-drug Interaction Study of KL1333 in Healthy Subjects","status":"COMPLETED","sponsor":"Abliva AB","startDate":"2020-11-10","conditions":"Mitochondrial Disease","enrollment":14},{"nctId":"NCT03056209","phase":"PHASE1","title":"Safety, Tolerability and Pharmacokinetic Study of KL1333 in Healthy Male Volunteers","status":"COMPLETED","sponsor":"Yungjin Pharm. Co., Ltd.","startDate":"2017-06-26","conditions":"MELAS Syndrome, Mitochondrial Respiratory Chain Deficiencies","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"KL1333","genericName":"KL1333","companyName":"Abliva AB","companyId":"abliva-ab","modality":"Small molecule","firstApprovalDate":"","aiSummary":"KL1333 is a small molecule that targets the mitochondrial permeability transition pore (mPTP) to induce cell death in cancer cells. Used for Treatment of various types of cancer, including glioblastoma and melanoma.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}